NCT00532389View on ClinicalTrials.gov

Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Multiple Myeloma
Interventions
DRUG

LBH589

Trial Locations (16)

2606

Novartis Investigative Site, Canberra

10117

Novartis Investigative Site, Berlin

10126

Novartis Investigative Site, Torino

24105

Novartis Investigative Site, Kiel

33138

Innovative Medical Research of South Florida Dept.ofInnovativeMedResearch, Miami Shores

37007

Novartis Investigative Site, Salamanca

40138

Novartis Investigative Site, Bologna

80336

Novartis Investigative Site, München

97070

Novartis Investigative Site, Würzburg

02115

Dana Farber Cancer Institute Clinical Research Coordinator, Boston

07601

Hackensack University Medical Center Multiple Myeloma Division, Hackensack

Unknown

Swedish Medical Center Dept.ofSwedishMedicalCtr., Seattle

V5Z 1M9

Novartis Investigative Site, Vancouver

H1T 2M4

Novartis Investigative Site, Montreal

04103

Novartis Investigative Site, Leipzig

08036

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY